A pipeline of realisation

With transplantation as the optimal therapeutic and translational launchpad, we aim maximise the full potential of Treg cell therapies and enable seamless expansion into autoimmune and inflammatory diseases

Our Pipeline

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

QEL-001 (A2-CAR)

For Liver Transplantation

Liberate

Phase 2

QEL-004 (Pan-Liver CAR)

For Liver Transplantation

Preclinical

QEL-002

For Type 1 Diabetes

Preclinical

QEL-003

For Inflammatory Bowel Disease

Preclinical

Discovery Programmes

Multiple research programmes

Discovery

QEL-ALLO

iPSC-Derived Treg Programmes

Discovery

Transplantation

Autoimmunity

iPSC-derived Tregs

QEL-001

For Liver Transplantation

making transplant the cure it was always intended to be

QEL-001 is our pioneering Treg therapy, an HLA-A2 targeted approach, aimed at inducing operational tolerance in HLA-A2 mismatched liver transplant recipients. This trailblazing approach looks to eliminate the need for lifelong immunosuppressive medication by allowing the immune system to accept transplanted organs as its own.

This product has the opportunity to expand into other HLA-A2 mismatched transplantations, including kidney, heart, lung and islet.

Phase 1/2 trial ongoing

Lifelong immunosuppression following liver transplantation dramatically increases the risk of infections, cancers, and organ complications, leading to higher mortality rates among patients - with 10 year survival rates post transplant as low as many common malignancies.

Eliminating this would be a gamechanger.

This product has the opportunity to expand into other HLA-A2 mismatched transplantations, including kidney, heart, lung and islet.

QEL-002

For Type 1 Diabetes

In collaboration with

CAR-Treg T1D QEL-002 represents Quell's commitment to expand the application of Treg therapies beyond transplantation. This islet targeted CAR-Treg therapy for type 1 diabetes aims to halt the inflammatory response against the pancreas in early onset type 1 diabetes patients - preventing further beta cell loss, durably controlling dysglycemia and reducing eliminating the need for exogenous insulin.

Poor glycaemic control following shortly after type 1 diabetes onset is associated with a significant risk of developing severe complications such as cardiovascular disease, kidney damage, retinopathy and neuropathy. Inadequate management not only diminishes quality of life but also elevates the risk of early mortality, underscoring the critical need for effective and timely diabetes control.

QEL-003

For Inflammatory Bowel Disease

In collaboration with

Quell is developing a CAR-Treg therapy for inflammatory bowel disease to durably reset the aberrant immune response and prevent tissue damage in the gut of patients unresponsive to currently available early-stagetreatments.

A significant proportion of IBD patients are refractory to multiple lines of therapy, suffering from severe, persistent symptoms that lead to complications. This leads to, frequent hospitalizations, and a heightened risk of surgery, underscoring the urgent need for transformative more radical and effective treatment options to arrest the disease process and break the cycle of lifelong relapses causing cumulative tissue damage.

QEL-ALLO

iPSC-Derived Treg Programmes

Following confirmation of autologous Treg cell therapy efficacy, we aim to surmount the biological challenges of cell therapy administration through the development of off-the-shelf, universally dosable Treg cells.

Multiple Early Research Programmes

Quell is advancing multiple early-stage research programs targeting distinct therapeutic areas, including neuroinflammation and rheumatology, to unlock the maximum potential of Treg cell therapies in indications with high unmet need.